Johns Hopkins Medicine has been awarded a multi-million dollar grant from the National Institutes of Health (NIH) to research the potential impact of psilocybin therapy to help tobacco smokers quit.
The nearly US$4-million grant is funded by the NIH’s National Institute on Drug Abuse, and it’s the first federal grant to be awarded for psychedelic treatment research in 50 years.
“The historical importance of this grant is monumental,” said principal investigator Matthew Johnson, who started the line of research testing the impact of psilocybin on tobacco cessation 13 years ago.
“We knew it was only a matter of time before the NIH would fund this work because the data are so compelling, and because this work has demonstrated to be safe. Psilocybin does have very real risks, but these risks are squarely mitigated in controlled settings through screening, preparation, monitoring and follow-up care.”
A 2014 pilot study of psilocybin treatment for long-term smokers showed an abstinence rate of 80 per cent after six months, “substantially higher than typical success rates in smoking cessation trials,” Johnson said previously.
The double-blind randomized trial uses psilocybin sessions and cognitive behaviour therapy, a type of talk therapy that aims to pinpoint negative thought patterns that can affect behaviour and mental health.
Johns Hopkins will lead the three-year study in collaboration with the University of Alabama at Birmingham and New York University. All three institutions will conduct the study simultaneously to diversify the participant pool so the results apply to a wide range of people who smoke.
Johns Hopkins notes a “growing renaissance of research with classic psychedelics” in the last 20 years largely funded by philanthropy that has shown “impressive” clinical findings for cancer-related existential distress, major depressive disorder and substance use disorders.
— Matthew W. Johnson (@Drug_Researcher) October 18, 2021
There’s been an increase in government attention to the therapeutic benefits of psychedelics, as federal agencies acknowledge the value of the research.
In June, NIH director Dr. Francis S. Collins expressed support for cannabis and psychedelic research, and said the agencies have begun to realize psychedelics are potential tools for medical research.
The Drug Enforcement Agency recently requested significantly increasing production quotas for synthesizing, extracting and manufacturing schedule I drugs, including psilocybin.
The post Can psilocybin help smokers quit? Johns Hopkins to study impact with NIH grant appeared first on Mugglehead Magazine.psilocybin psychedelic psychedelic research drug production therapy major depressive disorder depressive disorder depression antidepressant psychedelics funding fund fda research
Getting Ahead of the Psychedelics Supply Crunch
UK’s medical pot industry could reach £1.2B through reform: report
Cybin Gets FDA Approval For New Phase 2 Trial
CBD, ‘Snake Oil’ or Life-Changing?
New Study Shows Mushrooms Can Reverse Alcohol Brain Damage
Cell wall remodeling enables fungal network development in grasses
Are Reopening Penny Stocks Worth Buying After the Market Crash?
BigID Announces Auto-Discovery Apps For Cloud At AWS Re:Invent
Compass Phase 2 Study Shows Positive Results For TRD
Common antidepressant escitalopram and psilocybin can be taken together safely: study
Public Companies11 hours ago
Bright Minds Bioscience: A Deep Dive
Psilocybin12 hours ago
Florida Lawmaker Files Bill to Decriminalize All Drugs
Markets & Investing9 hours ago
Microdose Psychedelic Capital: Ethics in Psychedelics
Psychedelics9 hours ago
Psychedelic Titans with Larry Zeifman of Zeifmans LLP
MDMA6 hours ago
Rick Doblin Explains MAPS’ New $70 Million Investment Fund With Vine Ventures
Law & Regulation5 hours ago
THC biomarkers ‘poor’ indicators of impairment, study shows
Psilocybin16 hours ago
AREV Life Sciences / Absolem JV Receives Extraction Results
Psilocybin14 hours ago
Magic Mushrooms for Mental Health: A Look at Anxiety, Depression, and Bi-Polar Disorder